Discussion of a new monoclonal antibody, ianalumab (previously known as VAY736), targeting the B-cell activating factor (BAFF) receptor. We refer to the compound as VAY736 for consistency with the interview and abstract for this article.
Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
One click to our most popular content.